QVAR is the first Teva Respiratory brand with the device.
Teva Pharmaceutical Industries Ltd., (TEVA) announced on Friday that the US Food and Drug Administration (FDA) had approved the use of QVAR (beclomethasone dipropionate HFA) with a dose counter for the ongoing treatment of asthma as a preventative therapy in patients five years of age and older. The dose counter is designed to help asthma patients, as well as their caregivers, keep track of the number of doses remaining in the canister. The new product will be commercially available later this year.
“Bringing QVAR with a dose counter to market reaffirms Teva’s commitment to addressing unmet needs by providing high-quality and innovative solutions to patients,” said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. “Adding to our rich heritage within the respiratory space, we are pleased that all Teva Respiratory brands in the US will soon include a dose counter, which will help patients and caregivers track how many doses of their medication remain.”
Published by Globes [online], Israel business news - www.globes-online.com - on May 25, 2014
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013